---
id: acip-adult-immunization-2025
title: "ACIP Recommended Adult Immunization Schedule â€” United States, 2025"
short_title: "ACIP Adult Immunization 2025"

organization: Advisory Committee on Immunization Practices
collaborators: null
country: US
url: https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html
doi: null
pmid: 39820474
open_access: true

specialty: general-preventive
guideline_type: clinical-practice
evidence_system: null
conditions:
  - immunization
  - vaccination
tags:
  - influenza
  - RSV
  - COVID-19
  - pneumococcal

publication_date: 2025-01-01
previous_version_date: 2024-01-01
status: current
supersedes: acip-adult-immunization-2024
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-22
---

## Scope
Consolidated summary of ACIP recommendations for adult vaccination (ages 19 years and older).

## Key Changes for 2025

### Influenza
- Changed from quadrivalent to **trivalent formulation** per FDA approval for 2024-25 season
- Age 19+: 1 dose annually of age-appropriate vaccine
- Age 65+: Prefer HD-IIV3, RIV3, or aIIV3; use any age-appropriate vaccine if preferred not available

### RSV (Respiratory Syncytial Virus)
- **Age 60+**: Single dose of Arexvy, Abrysvo, or mResvia
- **Age 50-59 at increased risk**: May receive single dose
- Best administered late summer/early fall (August-October)
- Additional doses not recommended

### Pneumococcal Vaccines
- Not previously received PCV13/PCV15/PCV20/PCV21: 1 dose PCV15, PCV20, or PCV21
- If PCV15 used: Administer PPSV23 at least 1 year after

### COVID-19
- Updated recommendations for current vaccine formulations
- See current CDC guidance for specific product recommendations

### Meningococcal Serogroup B
- Updated recommendations based on risk factors

### Other Updates
- **Hepatitis B (HepB)**: Clarifications in notes
- **Mpox**: Clarifications in notes
- **Tdap**: Clarifications in notes
- **Inactivated Polio Vaccine**: Added to tables

## Routine Adult Vaccines

| Vaccine | Ages 19-26 | Ages 27-49 | Ages 50-64 | Ages 65+ |
|---------|------------|------------|------------|----------|
| Influenza | Annual | Annual | Annual | Annual (prefer high-dose) |
| Tdap/Td | 1 Tdap, then Td every 10y | Td every 10y | Td every 10y | Td every 10y |
| MMR | 1-2 doses if not immune | 1-2 doses if not immune | - | - |
| Varicella | 2 doses if not immune | 2 doses if not immune | - | - |
| Zoster (RZV) | - | - | 2 doses | 2 doses |
| HPV | Through age 26 | Shared decision 27-45 | - | - |
| Pneumococcal | Risk-based | Risk-based | Risk-based | 1 dose PCV + PPSV23 |
| RSV | - | - | Risk-based 50-59 | 1 dose 60+ |

## Resources
- Full schedule: https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html
- Individual vaccine recommendations: https://www.cdc.gov/acip-recs/hcp/vaccine-specific/index.html
